Boston, MA 10/01/2014 (wallstreetpr) – An aesthetic and therapeutic development stage biotechnology company, Fibrocell Science Inc (NASDAQ:FCSC) disclosed that it would be participating in the fourth annual partnering forum to be in California on October 7. The forum was part of a stem cell meeting.
To Discus Autologus Fibroblast Technology
Fibrocell Science Inc (NASDAQ:FCSC) indicated that it would be represented by its VP for Scientific Affairs, John Maslowski, in the Forum, its statement disclosed. The company said that its Scientific Affairs executive would discuss its autologous fibroblast technology besides its therapeutic candidates, which were in the development stage focused towards genetically-modified personalized biologics.
It would be a three-day event on the Mesa that was aimed to bring senior members from the regenerative medicine industry together with the science research professionals to move on the cutting-edge research into cures. The meeting was organized by the California Institute for Regenerative Medicine or CIRM and Alliance for Regenerative Medicine or ARM. It was the only and first partnering meeting dedicated mainly to facilitate connections for advanced therapies and regenerative medicine industry.
Fibrocell Science said that the meeting would also have a nationally familiar Scientific Symposium on October 9 at the Salk Institute for Biological Studies exhibiting most important academic research in the regenerative medicine field. More than 800 attendees were expected to throng the meeting from the world, which would foster key alliances by having one-to-one meetings and at the same time highlight commercial and clinical progress in the field.
To File NDA
A few days back, Fibrocell Science Inc (NASDAQ:FCSC) said that along with Intrexon Corp (NYSE:XON) it was planning to file an Investigational New Drug or IND application with the Food and Drug Administration or the FDA for their drug candidate before the first six-month period of the next year. The company indicated that the drug candidate was meant to treat recessive dystrophic epidermolysis bullosa or RDEB.
